Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Retained Earnings (2016 - 2025)

Sunshine Biopharma's Retained Earnings history spans 14 years, with the latest figure at -$75.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 8.65% year-over-year to -$75.0 million; the TTM value through Dec 2025 reached -$75.0 million, down 8.65%, while the annual FY2025 figure was -$75.0 million, 8.65% down from the prior year.
  • Retained Earnings reached -$75.0 million in Q4 2025 per SBFM's latest filing, down from -$320841.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $696105.0 in Q4 2023 to a low of -$75.0 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$26.9 million, with a median of -$27.8 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: tumbled 688217.34% in 2021, then surged 330.1% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$32.7 million in 2021, then surged by 100.5% to $161847.0 in 2022, then surged by 330.1% to $696105.0 in 2023, then plummeted by 10018.01% to -$69.0 million in 2024, then dropped by 8.65% to -$75.0 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Retained Earnings are -$75.0 million (Q4 2025), -$320841.0 (Q3 2025), and -$72.0 million (Q2 2025).